nidrendipine trial summary

Diabetes type 2

Patients with hypertension: 1 trials - Syst-Eur (diabetic subgroup)

No demonstrated result

suggested cardiovascular events by 62% (not demonstrated)

suggested Cardiovascular death by 70% (not demonstrated)

suggested stroke (fatal and non fatal) by 68% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.38 [0.19 0.76]	p=0.04	0	492	1	Syst-Eur (diabetic subgroup),
Cardiovascular death	0.30 [0.11 0.83]	p=0.04	0	492	1	Syst-Eur (diabetic subgroup),
myocardial infarction (fatal and non fatal)	0.44 [0.18 1.11]	p=1.00	0	492	1	Syst-Eur (diabetic subgroup),
stroke (fatal and non fatal)	0.32 [0.11 0.89]	p=0.04	0	492	1	Syst-Eur (diabetic subgroup),
microvascular events	no data
Non fatal MI	no data
All cause death	0.59 [0.31 1.11]	p=1.00	0	492	1	Syst-Eur (diabetic subgroup),
Non fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

Patients with or without hypertension: 1 trials - Syst-Eur (diabetic subgroup)

nitrendipine vs placebo

No demonstrated result

suggested cardiovascular events by 62% (not demonstrated)

suggested Cardiovascular death by 70% (not demonstrated)

suggested stroke (fatal and non fatal) by 68% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.38 [0.19 0.76]	p=0.04	0	492	1	Syst-Eur (diabetic subgroup),
Cardiovascular death	0.30 [0.11 0.83]	p=0.04	0	492	1	Syst-Eur (diabetic subgroup),
myocardial infarction (fatal and non fatal)	0.44 [0.18 1.11]	p=1.00	0	492	1	Syst-Eur (diabetic subgroup),
stroke (fatal and non fatal)	0.32 [0.11 0.89]	p=0.04	0	492	1	Syst-Eur (diabetic subgroup),
microvascular events	no data
Non fatal MI	no data
All cause death	0.59 [0.31 1.11]	p=1.00	0	492	1	Syst-Eur (diabetic subgroup),
Non fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Hypertension

All type of patient: 1 trials - SYST-EUR

nitrendipine vs placebo

No demonstrated result

suggested cardiovascular events by 29% (not demonstrated)

suggested stroke (fatal and non fatal) by 41% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.71 [0.57 0.89]	p=0.04	0	4695	1	SYST-EUR,
Cardiovascular death	0.73 [0.52 1.04]	p=1.00	0	4695	1	SYST-EUR,
stroke (fatal and non fatal)	0.59 [0.41 0.84]	p=0.04	0	4695	1	SYST-EUR,
Coronary event	0.75 [0.49 1.14]	p=1.00	0	4695	1	SYST-EUR,
Fatal MI	0.45 [0.18 1.10]	p=1.00	0	4695	1	SYST-EUR,
Non fatal MI	no data
Heart failure	0.75 [0.49 1.14]	p=1.00	0	4695	1	SYST-EUR,
Diabetes onset	no data
Angina	no data
Peripheral arterial disease	no data
End stage renal disease	no data
Revascularization	no data
All cause death	0.86 [0.67 1.10]	p=1.00	0	4695	1	SYST-EUR,
Fatal stroke	0.73 [0.38 1.40]	p=1.00	0	4695	1	SYST-EUR,
Non fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

Diabetic patients : 1 trials - Syst-Eur (diabetic subgroup)

nitrendipine vs placebo

No demonstrated result

suggested cardiovascular events by 62% (not demonstrated)

suggested Cardiovascular death by 70% (not demonstrated)

suggested stroke (fatal and non fatal) by 68% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.38 [0.19 0.76]	p=0.04	0	492	1	Syst-Eur (diabetic subgroup),
Cardiovascular death	0.30 [0.11 0.83]	p=0.04	0	492	1	Syst-Eur (diabetic subgroup),
myocardial infarction (fatal and non fatal)	0.44 [0.18 1.11]	p=1.00	0	492	1	Syst-Eur (diabetic subgroup),
stroke (fatal and non fatal)	0.32 [0.11 0.89]	p=0.04	0	492	1	Syst-Eur (diabetic subgroup),
microvascular events	no data
Non fatal MI	no data
All cause death	0.59 [0.31 1.11]	p=1.00	0	492	1	Syst-Eur (diabetic subgroup),
Non fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Elderly (60 years and more): 1 trials - SYST-EUR

nitrendipine vs placebo

No demonstrated result

suggested cardiovascular events by 29% (not demonstrated)

suggested stroke (fatal and non fatal) by 41% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.71 [0.57 0.89]	p=0.04	0	4695	1	SYST-EUR,
Cardiovascular death	0.73 [0.52 1.04]	p=1.00	0	4695	1	SYST-EUR,
stroke (fatal and non fatal)	0.59 [0.41 0.84]	p=0.04	0	4695	1	SYST-EUR,
Coronary event	0.75 [0.49 1.14]	p=1.00	0	4695	1	SYST-EUR,
Fatal MI	0.45 [0.18 1.10]	p=1.00	0	4695	1	SYST-EUR,
Non fatal MI	no data
Heart failure	0.75 [0.49 1.14]	p=1.00	0	4695	1	SYST-EUR,
Diabetes onset	no data
Angina	no data
Peripheral arterial disease	no data
End stage renal disease	no data
Revascularization	no data
All cause death	0.86 [0.67 1.10]	p=1.00	0	4695	1	SYST-EUR,
Fatal stroke	0.73 [0.38 1.40]	p=1.00	0	4695	1	SYST-EUR,
Non fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Uncomplicated hypertension: 1 trials - SYST-EUR

nitrendipine vs placebo

No demonstrated result

suggested cardiovascular events by 29% (not demonstrated)

suggested stroke (fatal and non fatal) by 41% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.71 [0.57 0.89]	p=0.04	0	4695	1	SYST-EUR,
Cardiovascular death	0.73 [0.52 1.04]	p=1.00	0	4695	1	SYST-EUR,
stroke (fatal and non fatal)	0.59 [0.41 0.84]	p=0.04	0	4695	1	SYST-EUR,
Coronary event	0.75 [0.49 1.14]	p=1.00	0	4695	1	SYST-EUR,
Fatal MI	0.45 [0.18 1.10]	p=1.00	0	4695	1	SYST-EUR,
Non fatal MI	no data
Heart failure	0.75 [0.49 1.14]	p=1.00	0	4695	1	SYST-EUR,
Diabetes onset	no data
Angina	no data
Peripheral arterial disease	no data
End stage renal disease	no data
Revascularization	no data
All cause death	0.86 [0.67 1.10]	p=1.00	0	4695	1	SYST-EUR,
Fatal stroke	0.73 [0.38 1.40]	p=1.00	0	4695	1	SYST-EUR,
Non fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Very ederly (80 and more): 1 trials - Syst-Eur (subgroup )

nidrendipine vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	n	k	trials
cardiovascular events	0.95 [0.59 1.54]	p=1.00	441	1	Syst-Eur (subgroup ),
Cardiovascular death	1.08 [0.62 1.87]	p=1.00	441	1	Syst-Eur (subgroup ),
stroke (fatal and non fatal)	0.77 [0.39 1.52]	p=1.00	441	1	Syst-Eur (subgroup ),
Coronary event	1.10 [0.53 2.30]	p=1.00	441	1	Syst-Eur (subgroup ),
Coronary death	1.16 [0.51 2.61]	p=1.00	441	1	Syst-Eur (subgroup ),
Heart failure	0.85 [0.40 1.80]	p=1.00	441	1	Syst-Eur (subgroup ),
All cause death	1.23 [0.81 1.88]	p=1.00	441	1	Syst-Eur (subgroup ),
Fatal stroke	1.01 [0.40 2.54]	p=1.00	441	1	Syst-Eur (subgroup ),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Nidrendipine calcium channel blockers

Diabetes type 2

Hypertension